docetaxel + nivolumab + ramucirumab + viagenpumatucel-L

This is a combination therapy for advanced non-small cell lung cancer (NSCLC), particularly in patients who have progressed on prior treatments. The regimen includes four agents with distinct mechanisms of action:\n\n- **Docetaxel**: A taxane chemotherapy that inhibits microtubule depolymerization, leading to cell cycle arrest and apoptosis.\n- **Nivolumab**: A monoclonal antibody targeting the programmed death-1 (PD-1) receptor, acting as an immune checkpoint inhibitor to enhance T-cell-mediated anti-tumor responses.\n- **Ramucirumab**: A monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis and tumor blood supply.\n- **Viagenpumatucel-L (HS-110)**: An allogeneic cellular immunotherapy derived from a human lung adenocarcinoma cell line expressing multiple tumor-associated antigens and transfected with gp96-Ig. It acts as a cancer vaccine by stimulating the patient’s immune system to recognize and attack NSCLC cells through cross-presentation of antigens via MHC I, leading to CD8+ T-cell activation[6][3][2].\n\nThis combination aims to synergize chemotherapy, antiangiogenic therapy, checkpoint inhibition, and active immunotherapy for improved efficacy in refractory NSCLC.